Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

From Burnout to Resilience: An Update for Oncologists.

Murali K, Makker V, Lynch J, Banerjee S.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):862-872. doi: 10.1200/EDBK_201023.

2.

Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Schlappe BA, Weaver AL, Ducie JA, Eriksson AGZ, Dowdy SC, Cliby WA, Glaser GE, Soslow RA, Alektiar KM, Makker V, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152-1. doi: 10.1016/j.ygyno.2018.08.022. [Epub ahead of print]

PMID:
30177461
3.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Aug 1. doi: 10.1158/1078-0432.CCR-18-0412. [Epub ahead of print]

PMID:
30068706
4.

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Burger RA, Deng W, Makker V, Collins Y, Gray H, Debernardo R, Martin LP, Aghajanian C.

Gynecol Oncol. 2018 Sep;150(3):466-470. doi: 10.1016/j.ygyno.2018.06.017. Epub 2018 Jul 3.

PMID:
30041929
5.

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report.

Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V.

Gynecol Oncol Rep. 2018 Jun 1;25:74-77. doi: 10.1016/j.gore.2018.05.014. eCollection 2018 Aug.

6.

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors.

Martin M, Sabari JK, Turashvili G, Halpenny DF, Rizvi H, Shapnik N, Makker V.

Gynecol Oncol Rep. 2018 Apr 18;24:94-98. doi: 10.1016/j.gore.2018.04.004. eCollection 2018 May.

7.

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA.

Clin Cancer Res. 2018 May 29. doi: 10.1158/1078-0432.CCR-18-0494. [Epub ahead of print]

PMID:
29844129
8.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

PMID:
29757876
9.

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.

Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar M.

Clin Cancer Res. 2018 Jun 15;24(12):2749-2757. doi: 10.1158/1078-0432.CCR-17-1775. Epub 2018 Mar 20.

PMID:
29559563
10.

Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12].

Martin M, Grisham RN, Turashvili G, Halpenny DF, Aghajanian CA, Makker V.

Gynecol Oncol Rep. 2017 Sep 29;22:118. doi: 10.1016/j.gore.2017.09.014. eCollection 2017 Nov.

11.

New therapies for advanced, recurrent, and metastatic endometrial cancers.

Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS.

Gynecol Oncol Res Pract. 2017 Dec 2;4:19. doi: 10.1186/s40661-017-0056-7. eCollection 2017. Review.

12.

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation.

Martin M, Grisham RN, Turashvili G, Halpenny DF, Aghajanian CA, Makker V.

Gynecol Oncol Rep. 2017 Sep 6;22:9-12. doi: 10.1016/j.gore.2017.09.001. eCollection 2017 Nov. Erratum in: Gynecol Oncol Rep. 2017 Sep 29;22:118.

13.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

PMID:
28281183
14.

Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, Soslow RA, Iasonos A, Leitao MM, Abu-Rustum NR.

Ann Surg Oncol. 2017 Jul;24(7):1965-1971. doi: 10.1245/s10434-017-5816-4. Epub 2017 Mar 3.

15.

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).

Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, Gilbert HN, Ware JA, Zhu R, Lu S, Huw LY, Wang Y, Koeppen H, Spoerke JM, Lackner MR, Aghajanian CA.

Cancer. 2016 Nov 15;122(22):3519-3528. doi: 10.1002/cncr.30286. Epub 2016 Sep 7.

16.

Nonbacterial thrombotic endocarditis with embolic cerebral vascular accidents in a patient with advanced, recurrent clear cell carcinoma of the ovary: A case report.

Liang LW, Perez AR, Cangemi NA, Young RJ, Makker V.

Gynecol Oncol Rep. 2016 Mar 17;16:25-7. doi: 10.1016/j.gore.2016.03.003. eCollection 2016 Apr.

17.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ 2nd, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF.

Gynecol Oncol. 2016 Apr;141(1):43-8. doi: 10.1016/j.ygyno.2016.02.025.

18.

An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.

Liang LW, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V.

Int J Gynecol Cancer. 2016 Mar;26(3):497-504. doi: 10.1097/IGC.0000000000000635.

19.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

20.

Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, Alektiar KM, Makker V, Iasonos A, Abu-Rustum NR.

Ann Surg Oncol. 2016 Jan;23(1):196-202. doi: 10.1245/s10434-015-4612-2. Epub 2015 May 21.

21.

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

Makker V, Filiaci VL, Chen LM, Darus CJ, Kendrick JE, Sutton G, Moxley K, Aghajanian C.

Gynecol Oncol. 2015 Jul;138(1):24-9. doi: 10.1016/j.ygyno.2015.04.006. Epub 2015 Apr 16.

22.

Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma.

Desai NB, Kollmeier MA, Makker V, Levine DA, Abu-Rustum NR, Alektiar KM.

Gynecol Oncol. 2014 Oct;135(1):49-53. doi: 10.1016/j.ygyno.2014.07.097. Epub 2014 Jul 30.

PMID:
25084509
23.

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.

Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JJ 2nd, Zweizig SL, Van Le L, Hanjani P, Downey G, Walker JL, Reyes HD, Leslie KK.

Gynecol Oncol. 2014 Mar;132(3):585-92. doi: 10.1016/j.ygyno.2014.01.015. Epub 2014 Jan 20.

24.

Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.

Makker V, Kravetz SJ, Gallagher J, Orodel OP, Zhou Q, Iasonos A, DeLair D, Aghajanian C, Hensley ML.

Int J Gynecol Cancer. 2013 Nov;23(9):1635-41. doi: 10.1097/IGC.0000000000000001.

PMID:
24172099
25.

Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Kim CH, Khoury-Collado F, Barber EL, Soslow RA, Makker V, Leitao MM Jr, Sonoda Y, Alektiar KM, Barakat RR, Abu-Rustum NR.

Gynecol Oncol. 2013 Dec;131(3):714-9. doi: 10.1016/j.ygyno.2013.09.027. Epub 2013 Oct 4.

26.

Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.

Desai NB, Kiess AP, Kollmeier MA, Abu-Rustum NR, Makker V, Barakat RR, Alektiar KM.

Gynecol Oncol. 2013 Dec;131(3):604-8. doi: 10.1016/j.ygyno.2013.09.019. Epub 2013 Sep 20.

PMID:
24055615
27.

Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer.

Milgrom SA, Kollmeier MA, Abu-Rustum NR, Makker V, Gardner GJ, Barakat RR, Alektiar KM.

Gynecol Oncol. 2013 Jul;130(1):49-53. doi: 10.1016/j.ygyno.2013.04.013. Epub 2013 Apr 16.

28.
29.

Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival.

Teckie S, Makker V, Tabar V, Alektiar K, Aghajanian C, Hensley M, Beal K.

Radiat Oncol. 2013 Feb 15;8:36. doi: 10.1186/1748-717X-8-36.

30.

Radical surgery with individualized postoperative radiation for stage IB cervical cancer: oncologic outcomes and severe complications.

Sandadi S, Tanner EJ, Khoury-Collado F, Kostolias A, Makker V, Chi DS, Sonoda Y, Alektiar KM, Barakat RR, Abu-Rustum NR.

Int J Gynecol Cancer. 2013 Mar;23(3):553-8. doi: 10.1097/IGC.0b013e3182849d53.

PMID:
23392402
31.

Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome.

Hyman DM, Bakios L, Gualtiere G, Carr C, Grisham RN, Makker V, Sonoda Y, Aghajanian C, Jewell EL.

Gynecol Oncol. 2013 Apr;129(1):58-62. doi: 10.1016/j.ygyno.2012.12.029. Epub 2012 Dec 26.

PMID:
23274560
32.

Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.

Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM.

Gynecol Oncol. 2013 Feb;128(2):288-93. doi: 10.1016/j.ygyno.2012.11.012. Epub 2012 Nov 15.

PMID:
23159818
33.

A prospective study of quality of life in patients undergoing pelvic exenteration: interim results.

Rezk YA, Hurley KE, Carter J, Dao F, Bochner BH, Aubey JJ, Caceres A, Einstein MH, Abu-Rustum NR, Barakat RR, Makker V, Chi DS.

Gynecol Oncol. 2013 Feb;128(2):191-7. doi: 10.1016/j.ygyno.2012.09.030. Epub 2012 Oct 9.

34.

Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.

Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM.

Gynecol Oncol. 2012 Nov;127(2):321-5. doi: 10.1016/j.ygyno.2012.07.112. Epub 2012 Jul 28.

PMID:
22850412
35.

Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer.

Alektiar KM, Makker V, Abu-Rustum NR, Soslow RA, Chi DS, Barakat RR, Aghajanian CA.

Gynecol Oncol. 2009 Jan;112(1):142-5. doi: 10.1016/j.ygyno.2008.10.006. Epub 2008 Nov 20.

36.

A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.

Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, Iasonos A, Hensley ML.

Gynecol Oncol. 2008 Nov;111(2):249-54. doi: 10.1016/j.ygyno.2008.06.035. Epub 2008 Aug 27.

37.

The relation between vertebral endplate shape and lumbar disc herniations.

Harrington J Jr, Sungarian A, Rogg J, Makker VJ, Epstein MH.

Spine (Phila Pa 1976). 2001 Oct 1;26(19):2133-8.

PMID:
11698892

Supplemental Content

Loading ...
Support Center